Drug

Pelcitoclax clinical trials

Also written APG-1252.

studies test it: 10
open now: 2
in phase 3: 0
first study started: 2017

How each study uses pelcitoclax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pelcitoclax studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pelcitoclax: 5
APG-1252 for injection: 3

Development codes

APG-1252: 9

Studies by the year they started

10 studies that test it; most in 2017 (2)

Studies that test pelcitoclax, by start year
Year	Studies
2017	2
2019	1
2020	2
2022	2
2023	1
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 10
Phase 2: 4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Small Cell Lung Carcinoma: 3
Endometrial Neoplasms: 1
Lymphoma, Non-Hodgkin: 1
Neuroendocrine Tumors: 1
Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1
Primary Myelofibrosis: 1

Who runs them

Industry 7 · Other 3

Ascentage Pharma Group Inc. (7) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (1)

Often tested with

Tested in the same studies.

Lisaftoclax (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test pelcitoclax.

Feb 2027Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersPhase 1 · National Cancer Institute (NCI)

Studies

Open first, then newest update. How each study uses pelcitoclax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 10

Codes

What other systems call pelcitoclax · ClinicalTrials.gg INT001848

MeSH (NLM) C000722437pelcitoclaxConfirmed ClinicalTrials.gov, NLM
UNII (FDA) 317UBD60MLPELCITOCLAXConfirmed FDA, NLM
NCI Thesaurus C148488PelcitoclaxOne source FDA

System	Code	Name there	Checked by
MeSH (NLM)	C000722437	pelcitoclax	Confirmed ClinicalTrials.gov, NLM
UNII (FDA)	317UBD60ML	PELCITOCLAX	Confirmed FDA, NLM
NCI Thesaurus	C148488	Pelcitoclax	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.